⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 32 in last 7 days 🍎 Food: 1 in last 7 days 🧸 Products: 0 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 4 hours ago ⚠ LIVE — European Consumer Safety Watch 💊 Medicines: 32 in last 7 days 🍎 Food: 1 in last 7 days 🧸 Products: 0 in last 7 days 🟢 Monitoring: EMA · RASFF · NVWA · FAGG · FAVV · EFSA · Safety Gate ⏱ Last fetch: 4 hours ago
🛡️ EUSW
💊 Medicines 🍎 Food 🧸 Products 🔎 Search
📊 Data
🏷 Brands 🌍 Countries ℹ️ About ✉ Unsubscribe
🇬🇧
🇬🇧 English 🇳🇱 Nederlands 🇫🇷 Français 🇩🇪 Deutsch 🇪🇸 Español 🇮🇹 Italiano 🇵🇹 Português 🇵🇱 Polski 🇸🇪 Svenska 🇷🇴 Română 🇨🇿 Čeština 🇫🇮 Suomi 🇩🇰 Dansk
💊 Medicine EU July 11, 2023

Rybelsus

📷 Wikipedia: Semaglutide · Source
Rybelsus
📷 Wikipedia: Semaglutide · Source
INN
semaglutide
Forms
Tablet
Strengths
3 mg;7 mg;14 mg
Area
Diabetes Mellitus, Type 2
Alternatives
Yes
🗄
Archived (older alert)
This alert was reported 1158 days ago and has been moved from our active feed to the archive. The original safety information still applies — we have no confirmation from the issuing agency that the product is safe again. Refer to the official notice for the current status.
📈 Timeline
118 days in total
May 16, 2026 September 11, 2026
Daily snapshot data starts accumulating once the scheduler runs — for now this is interpolated from the agency's first/last dates.

What is this? Rybelsus is a tablet used to help people with type 2 diabetes control their blood sugar.

What's happening? There was a short supply of Rybelsus tablets in the EU, but the problem has been fixed.

Does this affect me? If you take Rybelsus, check with your pharmacist to see if your supply is back to normal.

What should I do? Do not stop taking your medicine without talking to your doctor or pharmacist first.

🤖 This plain-language summary is automatically generated from the official agency notice using AI. It is for general information only — not medical advice. For decisions about your health, always consult a pharmacist or doctor and read the official source linked below.

🔬 Medical / technical details (for professionals)
Active substance(s)
semaglutide
Brand(s) / product name(s)
Rybelsus
Agency-published detail

INN: semaglutide · Forms: Tablet · Strengths: 3 mg;7 mg;14 mg · Area: Diabetes Mellitus, Type 2 · Alternatives: Yes

First published
July 11, 2023
Last refreshed by us
3 months ago
Severity (as classified)
Medium
Official source
https://www.ema.europa.eu/en/medicines/human/shortages/rybelsus

All information on this page comes from the official agency notice. We translate and summarise it; we don't add or edit facts.

❓ Frequently asked questions

▸ What is this medicine shortage alert about?
Rybelsus. INN: semaglutide · Forms: Tablet · Strengths: 3 mg;7 mg;14 mg · Area: Diabetes Mellitus, Type 2 · Alternatives: Yes
▸ When was this alert issued?
This alert was issued on July 11, 2023 by EMA (European Medicines Agency).
▸ Which countries are affected?
The alert applies to the entire EU.
▸ How serious is this alert?
Medium risk. A medium risk means harm is possible under certain conditions. Read the notice and act on the recommended steps.
▸ What should I do?
If you take this medicine, contact your pharmacist or prescribing doctor. They can advise on alternative products or substitutes. Do not stop taking prescription medicine without medical advice.
▸ Where can I find the official notice?
The full official notice is published on www.ema.europa.eu.

💬 Discussion

Share your experience or ask a question. Real names and email are optional but moderation friendly.

No comments yet — be the first.

We email a confirmation link. Your address stays private.

⚠️ We aggregate official notices. We do not give medical advice. For medical or legal decisions, consult the source agency and a qualified professional.